Toviaz
Product Images NDC 54868-6175

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Toviaz (NDC 54868-6175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (4 mg Tablet Bottle Label)

This appears to be the label information for a medication called Toviaz 4G, which is distributed by Ngslclmswvm Care. The NDC and lot/expiry information are also provided on the label. The last line may be a batch or code number.*

FDA Label Image

Principal Display Panel (8 mg Tablet Bottle Label)

This is a description of a medication called Toviaz BHG Tab. It is distributed by Physicians Total Care and has an NDC code of 54868-6175-0. The medication comes from lot number 0060 and has an expiration date of 01460. The rest of the text is not readable.*

FDA Label Image

Chemical Structure (Toviaz 01)

FDA Label Image

Figure 1 (Toviaz 02)

The text describes a graph displaying the change in number of micturitions per 24 hours over the course of 12 weeks in Study 1. The graph shows the results for a placebo group (N=279) and a group taking Toviaz at either 4mg or 8mg doses. The mean change from baseline is plotted against weeks 2, 8, and 12.*

FDA Label Image

Figure 2 (Toviaz 03)

This is a chart displaying the change in urge incontinence episodes over a study of 12 weeks. The horizontal axis shows the number of weeks, and the vertical axis shows the change from baseline in the number of urge incontinence episodes per 24 hours. There are three treatment groups represented: a placebo group (N=211), a Toviaz 4mg group (N=139), and a Toviaz 8mg group (N=223).*

FDA Label Image

Figure 3 (Toviaz 04)

The text describes the mean change from baseline in the number of micturitions per 24 hours in Study 2. The change observed was -0.5 micturitions per 24 hours. There is also a graph (Figure 3) showing the change in the number of micturitions over time (weeks 2, 8, and 12) for the placebo group (N=266), the Toviazdmg group (N=267), and the Tovazsmg group (N=267).*

FDA Label Image

Figure 4 (Toviaz 05)

This is a graph that shows the change in urge incontinence episodes per 24 hours over a period of 12 weeks in Study 2. The graph includes three treatment groups: a Placebo group (205 participants), a Toviazdmg group (228 participants), and a Tovazsmg group (218 participants). The x-axis shows the weeks, and the y-axis shows the number of incontinence episodes. At Week 0, all groups had a similar number of incontinence episodes per 24 hours (around 0.0). Over the course of 12 weeks, there was a decrease in incontinence episodes in all three groups, with the Tovazsmg group showing the most significant reduction.*

FDA Label Image

Logo (Toviaz 06)

This appears to be an error. The text is not readable.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.